Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by GeorgeBasseton Dec 08, 2018 8:34pm
324 Views
Post# 29088010

Wallace likes NO and research

Wallace likes NO and researchWhat if ...

- NO INCREASES CANCER ? :

" Because the C. parvum–induced inflammation did not change the latency of tumor development in p53−/−NOS2−/− mice, the rapid tumor development in C. parvum–treated p53−/−NOS2+/+ mice is genetic evidence of a role of NO. We propose a dose-dependent model of NO-mediated modulation of tumorigenesis in p53-deficient mice, in which an increase in NO production under inflammatory conditions can inhibit apoptosis, increase proliferation, and modulate the immune profile, giving rise to an internal milieu that is conducive to the tumor growth. "
https://cancerres.aacrjournals.org/content/68/17/7130


- Different NO releasing molecules than those developped at ATE  are developed ?
- Chronically ill patients taking a constant dose of NO (an already body synthesized molecule)  creates chemical imbalances over the years ?
- The NO molecule gives bad breath and is not comercially viable ?


While we wait to get those answers, Citagenix can keep trying hard at growing ...




Bullboard Posts